Phase I study of [(131)I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. Thivat E, Rouanet J, Auzeloux P, Sas N, et al. BMC Cancer 2022;22:417.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thivat E, Rouanet J, Auzeloux P, Sas N, et al. Phase I study of [(131)I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer 2022;22:417.
PMID: 35428211